- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

New Delhi: In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organization (CDSCO) has asked Eisai Pharmaceuticals India Private Limited to submit complete safety data from its ongoing Phase IV clinical trial of Lenvatinib Capsules (4 mg and 10 mg) in patients with unresectable hepatocellular carcinoma (HCC).
The matter was taken up during the SEC (Oncology) meeting based on the company’s submission under application number SND/CT/19/000043. The firm presented the report of the Phase IV clinical trial conducted in Indian patients with unresectable HCC using Lenvatinib Capsules.
During the meeting, the committee noted that adverse events were reported during the course of the study. However, the firm did not present the complete details of these adverse events or provide any corresponding assessment reports explaining causality, severity, or resolution.
After detailed deliberation, the SEC recommended that Eisai Pharmaceuticals must submit the complete adverse event data and corresponding assessment reports related to the Phase IV study to CDSCO. These submissions will be required for further regulatory review and to determine the safety profile of the drug in the post-marketing setting.
"Submit the complete details of adverse events reported during the Phase IV CT study along with its assessment reports to CDSCO for further review by the committee," the expert panel noted.
Lenvatinib, an oral multikinase inhibitor, is approved for the treatment of unresectable hepatocellular carcinoma (HCC), one of the most common forms of liver cancer. It works by blocking multiple receptors involved in tumor angiogenesis and proliferation, including VEGFR, FGFR, and PDGFR.
Eisai Pharmaceuticals India Pvt. Ltd, a subsidiary of Eisai Co., Ltd., Japan, has a global presence in oncology, neurology, and rare diseases. The company markets Lenvatinib in India and other regions under its oncology portfolio and is conducting Phase IV trials as part of post-marketing surveillance obligations.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751